### Glasgow Clinical Trials Unit Guideline 55.001A Version 4.0 PV Office – Preparation of Sponsor Safety Reporting Plan, Glasgow Clinical Trials Unit (GCTU) Pharmacovigilance (PV) Office

# **Purpose of document:**

The purpose of this guideline is to outline the process for the development of a study specific Sponsor Safety Reporting Plan for each CTIMP and Clinical Investigations sponsored by NHS GGC or Co-sponsored with the University of Glasgow.

### **Personnel:**

Pharmacovigilance Administrator Pharmacovigilance and Safety Manager R&I Research Governance Manager

### **Background:**

A study specific Sponsor Safety Reporting Plan will be prepared for each CTIMP sponsored or cosponsored by NHS GGC, and clinical investigations of non CE marked medical devices. The Sponsor Safety Reporting Plan documents GCTU PV Office activities within the study and contains study specific information e.g. contact details, any risk adapted modifications to the reporting requirements, detailed information regarding the assignment of expectedness etc.

During the set up phase of the study the Pharmacovigilance and Safety Manager will prepare a draft plan using the Sponsor Safety Reporting Plan template (Form 55.001A). This will be modified with reference to the study protocol, the risk assessment, and any study agreements or contracts.

### **Content of PV Plan**

The following sections will be included when applicable:

Title page

- 1. Study personnel and contacts
- 2. Overview
- 3. Study Details
- 4. Organisation
- 5. Data Sources
- 6. Trial pharmacovigilance
- 7. SAE processing and reporting
- 8. SUSAR review and reporting
- 9. Coding
- 10. Quality
- 11. Related Documents

Draft Sponsor Safety Reporting Plans will be reviewed by the CI, the R&I Research Governance Manager, and the trial pharmacist where applicable. Draft Plans will also be circulated to the trial management group for review but their sign off is not required.

Sponsor Safety Reporting plans will be approved by the R&I Research Governance Manager and may be updated as required throughout the course of the trial.

#### Filing

Copies of the plan will be filed in:

Study Pharmacovigilance File (electronic and paper) CI Site File

#### **Related Documents:**

Form 55.001A-GCTU Sponsor Safety Reporting Plan Template

# **Document Details:**

Prepared by: Marc Jor	nes Signed	:	 Date:	/	/

Approved by: Caroline Watson Signed: ..... Date: / /

# **Document History:**

Version	Details	Date
1.0	Initial creation	29/11/2013
2.0	Change of Title, change to review process, index updated, addition of filing information	21/09/2015
3.0	Reviewed and released as part of SOPs reorganisation process. Guideline has moved to SOP category 55 NHS GG&C Sponsor Pharmacovigilance and renumbered (previously 18.001A). 'Prepared by' changed to Caroline Watson, 'Approved by' changed to Julie Brittenden.	15/07/2016
4.0	Updated in line with amendments to Form 55.001A and following discussions by the Sponsor PV Group	26/04/2021

This guideline is a controlled document. The current version can be viewed on the Unit's internet site. Any copy reproduced from the internet site may not, at time of reading, be the current